Broadcast Live   |   Upload & Publish  | About  | Register  | Sign in
E-mail:
Password:
Remember me on this computer
You need to install or upgrade your Flash Player!

3B NEXUS video platform & portal supports the latest version of Macromedia Flash player.


3B PLAYER by 3B NEXUS

Close [ X ]
Copy this code to embed & stream this video on your website
 
Copy this URL to share or create a link back to this video
Stefanos Theoharis, Ph.D.
Dir. Corporate Development
Germany
TGF-β2 Inhibitor Trabedersen - A promising immunological therapeutic option in aggressive cancers
Antisense - innovative therapeutic approach to inhibit the synthesis of pathogenic proteins. Antisense Pharma is committed to research and development of innovative medicines; pursuing an immunotherapeutic strategy with a potentially long-lasting effect against malignant tumor diseases.

[ close ] 
Please select the appropriate option to comply with legal regulations

Individual Investor Professional Investor or Financial Advisor
This multimedia channel includes videos, webcasts and live broadcasts suitable for members of the general public over 18 years of age and not engaged in providing investment advice. Access this channel for personal interest & information only. This multimedia channel includes investor videos and webcast presentations, live broadcasts and documents intended only for authorised and regulated professionals and financial advisers eligible to provide investment advice to private investors.
I comply with these terms I comply with these terms
Remember my choice for all channels on this portal Enter Media Channel »
No reliance should be placed on the information on this site which may change without notice.
You should read the Terms & Conditions section before browsing this site.

Search in Sort By
1 2 3 4 of 4   MORE   SHOW
  Select a title or search in slides to skip chapters
00:00
Stefanos Theoharis, Ph.D., Targeted Cancer Immunotherapy - TGF-B2 Inhibitor Trabedersen
00:10
oncology focused biotech company, Corporate Information
00:20
Private investors Venture capital funds , Investors
00:31
survival, leukaemia, myeloma, Only limited improvement over the last 40 years for some cancers
01:45
Chemotherapy, Targeted Therapy, Immunotherapy, High-grade glioma, Pancreatic cancer, Malignant melanoma , Targeted immunotherapy is the 3rd generation of cancer treatments
03:15
cancer indications, unmet medical need, High-grade glioma, Pancreatic Carcinoma, Malignant melanoma , Investigated cancer indications with high unmet medical need
03:58
TGF-B2, Immunosuppression, Metastasis, Angiogenesis, Tumor Growth , TGF-B2 has multi-modal cancer-promoting effects
04:45
Monoclonal Antibodies, Small Molecule Inhibitors, Antisense, Efficacy, Specificity, Safety, A successful anti-TGF-B2 campaign must fulfill a number of key criteria
05:45
Antisense Technology, Cancer protein, Nascent, Nucleus, pathogenic protein, Antisense molecules , Antisense Technology
06:18
Trabedersen, Antisense Molecules, Exceptional Efficacy Downregulation, Low COGS , Antisense efficiently downregulates protein synthesis at the translational level
07:00
Trabedersen, Clinical Phase, indications , Trabedersen is in advanced clinical development in various indications with very high unmet need
07:40
Trabedersen, survival benefit, Phase IIb, Anaplastic Astrocytoma , AA patients treated with Trabedersen have 17.4 months survival benefit
08:10
Trabedersen, survival rate, AA patients treated with Trabedersen show doubled 24-month survival rate
08:25
GBM subgroup, prognostic parameters, Trabedersen , Three-fold survival rate in GBM subgroup with the prognostic parameters < 55 yrs, KPS > 80%
09:15
survival benefit, pancreatic cancer patients, Trabedersen, Phase II study , Significant survival benefit expected in pancreatic cancer patients treated 2nd line with Trabede
10:06
Preliminary results, malignant melanoma, Ipilimumab, Preliminary results of P001 study showing high potential for Trabedersen in malignant melanoma
10:32
business opportunity, risk reward ratio, Market potential, Proof of concept , Unique business opportunity with promising risk/reward ratio
11:17
clinical efficacy, indications, High-grade glioma, Pancreatic cancer, Malignant melanoma , Summary: trabedersen shows impressive clinical efficacy and outcome in several indications
11:40
, Contact info